EEG Review of 23 Huntington's Studies Points to Alpha Loss, Delta Gain

A systematic review of 23 Huntington's disease (HD) EEG studies has found a consistent pattern: people with HD show reduced alpha power and increased delta power on resting-state scalp EEG, and these changes correlate with established clinical measures including Unified Huntington's Disease Rating Scale (uHDRS) scores and CAG repeat length.

Researchers and clinicians from the USA and Iran conducted the review, which compared resting-state and sleep EEG findings in individuals with HD against healthy controls. Their conclusion: scalp EEG activity is altered in HD and tracks with early cognitive symptoms, making the modality a candidate biomarker for disease progression.

What did the review actually find?

At rest, the studies converged on two findings. Alpha power (8–12 Hz) was consistently decreased in people with HD, while delta power (0.5–4 Hz) increased overall. The authors interpret this pattern, along with other changes, as evidence of widespread disruption in normal cortical communication — the brain is not functioning optimally in HD.

Sleep EEGs showed their own signature: reduced theta power (4–8 Hz), the band most active during sleep. Because sleep disturbances occur during HD progression and altered sleep may be linked to cognitive change, the authors suggest sleep EEG deserves further exploration as a biomarker, particularly for early disease.

Do EEG changes track clinical measures?

Several studies in the review paired EEG with clinical scales. Reduced alpha power and increased delta power were associated with HD progression as measured by uHDRS, which captures movement, cognition, and daily function.

In people who had not yet received an HD diagnosis, EEG changes correlated with higher CAG repeat lengths and greater disease burden scores. Taken together, the findings suggest EEG measures could reflect disease-related change across the full spectrum of HD progression — including the pre-manifest stage, which is exactly what a progression biomarker needs to do.

What remains unresolved is timing. EEG abnormalities become more pronounced as HD advances, but the review could not establish how soon they appear or whether they track the earliest symptoms. Additional cognitive testing would be needed to link the EEG changes to specific thinking and behavioral deficits.

Does medication confound the signal?

Several reviewed studies examined common HD medications — antidepressants, neuroleptics, benzodiazepines, and movement-control drugs such as tetrabenazine. In general, these treatments did not drastically alter EEG patterns.

That matters for clinical trial use. A biomarker that survives concomitant medication is far easier to deploy in trials where participants arrive on varied drug regimens.

Why EEG rather than MRI?

Cognitive changes occur early in HD, and EEG may be sensitive enough to detect underlying brain change even before symptoms appear. If confirmed, that would give trialists an objective, repeatable measure of treatment effect.

The practical case is straightforward. Scalp EEG is non-invasive, relatively inexpensive, and more accessible than brain imaging techniques such as MRI. It measures a different aspect of brain function than structural imaging — electrical signaling picked up by scalp electrodes — but it can be repeated cheaply and often.

What are the limitations?

The central weakness is study heterogeneity. Most EEG studies in HD have been small and have used different recording and analysis methods, which makes results hard to compare and pool. The review itself underscores the need for larger, standardized clinical studies before EEG can be validated as an HD biomarker.

The authors also flag juvenile-onset HD as untested territory — no conclusion can yet be drawn about whether EEG behaves similarly in that population.

The bottom line for the reading room

• Resting-state EEG in HD: decreased alpha power, increased delta power, consistent across studies.
• Sleep EEG in HD: reduced theta power, potentially useful in early disease.
• Common HD medications did not significantly distort the EEG signal.
• EEG changes correlate with uHDRS scores, CAG repeat length, and disease burden scores, including in pre-diagnosed individuals.
• Validation in larger, standardized cohorts — and in juvenile HD — remains outstanding.

For now, these are research-grade findings from small pooled studies, not a clinical indication for EEG in HD management. If follow-up work confirms the alpha–delta pattern as an early, medication-robust signal, EEG could become a low-cost endpoint for tracking treatment effects in HD trials.